5,128 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Callan Capital LLC

Callan Capital LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,128 shares of the biopharmaceutical company’s stock, valued at approximately $209,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of HALO. Alps Advisors Inc. bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth about $344,000. Townsquare Capital LLC lifted its position in Halozyme Therapeutics by 21.9% during the third quarter. Townsquare Capital LLC now owns 44,175 shares of the biopharmaceutical company’s stock worth $1,687,000 after acquiring an additional 7,949 shares during the last quarter. Verity Asset Management Inc. boosted its holdings in shares of Halozyme Therapeutics by 22.5% during the third quarter. Verity Asset Management Inc. now owns 31,310 shares of the biopharmaceutical company’s stock worth $1,196,000 after acquiring an additional 5,741 shares during the period. Aurora Investment Counsel acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $1,347,000. Finally, EP Wealth Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $211,000. Institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 109,755 shares in the company, valued at $5,488,847.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 40,000 shares of company stock valued at $1,858,100. 2.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Benchmark boosted their price target on Halozyme Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price target on shares of Halozyme Therapeutics in a research report on Monday, June 24th. Piper Sandler downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price objective for the company from $48.00 to $51.00 in a report on Friday, June 7th. Finally, JMP Securities decreased their target price on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.25.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock traded up $0.08 on Wednesday, reaching $52.96. 1,586,709 shares of the stock were exchanged, compared to its average volume of 1,258,043. The firm’s 50 day moving average is $47.18 and its 200-day moving average is $41.14. The firm has a market cap of $6.74 billion, a PE ratio of 21.85, a P/E/G ratio of 0.53 and a beta of 1.27. The company has a debt-to-equity ratio of 8.44, a quick ratio of 5.36 and a current ratio of 6.64. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $54.35.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The firm had revenue of $195.88 million during the quarter, compared to analysts’ expectations of $201.72 million. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.